Apricus Biosciences, Inc. (APRI) was a big mover last session with its shares rising roughly 8% on the day. The upside came on the company’s announcement that it has licensed the U.S. development and commercialization rights for Vitaros from Allergan plc (AGN). This development led to far more shares changing hands yesterday than in a normal session. The move breaks the recent trend of the company, as the stock is now trading above the past one month’s volatile price range of $1.14 to $1.78.
This drug manufacturer that developes products and product candidates in the areas of urology and rheumatology has seen one positive estimate revision in the last 30 days. The Zacks Consensus Estimate has also moved higher over the same time frame. This suggests solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s rally can turn into more strength down the road.
Apricus Biosciences currently has a Zacks Rank #2 (Sell) and its Earnings ESP is 0.00%.
Is APRI going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
APPRICUS BIOSCI (APRI): Free Stock Analysis Report
ALLERGAN PLC (AGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research